Shahrzad Shirazi Fard

Shahrzad Shirazi Fard

Anknuten till Forskning
Besöksadress: BioMedicum A4, Solnavägen 9, 17165 Solna
Postadress: K6 Kvinnors och barns hälsa, K6 Barnonkologi och Barnkirurgi Herold, 171 77 Stockholm
Del av:

Om mig

  • My research set out to investigate consequences of intra tumour cellular heterogeneity for the progression into refractory disease, with the objective to target residual disease and prevent metastasis. 


  • I obtained my PhD in 2014 from Uppsala University in developmental neuroscience. In my PhD-thesis I demonstrated that subpopulations of neuronal progenitor cells have innate properties that make them sensitive to tumor development. This illustrates the importance of understanding the heterogenic properties of developing tissues and relation to neoplastic formation. Following my PhD, I started a dual Post doc training in the group of prof. Lars Ährlund-Richter at Karolinska Institutet and in the group of Dr. Jan Mulder at SciLifeLab Karolinska Institutet. The research focused on a novel transplantation model for studying pediatric solid tumors together with a novel MULTIPLEX technique for enhanced correlation analysis of multiple cellular markers at the site of tumour metastasis. In September 2019 I obtained an Assistant Professorship at Karolinska Institutet.

Forskningsbeskrivning

  • Our research aims to decipher the complicated spatial interplay between tumour cells and the tumour microenvironment using MULTIPLEX genomic, transcriptomic and proteomic profiles in order to investigate consequences of tumour heterogeneity for the progression into refractory disease. 

  • Neuroblastoma is the most common extra cranial solid tumor in pediatrics and accounts for 15% of cancer related deaths in children. Even though the overall survival has increased following implementation of novel therapeutics one third of high-risk patients will experience treatment failure. An outcome most likely influenced by the tumour microenvironment. Spatial multi-omics techniques enable better dissection of the tumour microenvironment through investigation of the spatial architecture. A combination of several novel multiparameter immunofluorescence analysis techniques is being used on patient biopsies. The single-cell approach allows us to investigate cell-cell interactions that might contributing to resistance. This is combined by targeted treatment in matched in vivo cell lines of neuroblastoma, in order to re-sensitize resistant tumour cells to therapy. An enhanced understanding of the intra-tumour heterogeneity and asynchronous therapy responsiveness are among the most important areas in tumour research and our work is anticipated to produce novel biological discoveries and encourage further development of therapies. 

Undervisning

  • Recent teaching
    2024 and 2022 Course Leader - “Translational Paediatric Oncology in the Era of Immunotherapy and Omics”, KI PhD course
    2021 Teacher - “Translational Paediatric Oncology in the Era of Immunotherapy and Omics”, KI PhD course
    2020-2021 Teacher - Molecular Medicine and Oncology, KI Biomedicine program
    2019-2020 Teacher - DFM 1 course, course module Development – from egg to embryo, KI Medicine program

     

  • Supervisor
    2021 - ongoing (Co-supervisor) Ioanna Tsea PhD-student

    2023 Master thesis, Yuwei Lin, MSc, KTH
    2023 Master thesis, Alexandra Johansson, MSc, KTH
    2022 Master thesis, Maja Lundström, MSc, KTH
    2021 Master thesis, Mani Devaraj, MSc, KI
    2021 Master thesis, Agnes Sorteberg, MSc, KTH
    2021 Master thesis, Vesa Halipi, MSc, LTH
    2020 Master thesis, Maryam Sahi, MSc, KTH
    2020 Master thesis, Ximena Lopez Lorenzo, MSc, KTH
    2019 Master thesis, Linnéa Ödborn Jönsson MSc, KTH
    2018 Master thesis, Faye Keller MSc, Uppsala University

Artiklar

Alla övriga publikationer

Forskningsbidrag

Nyheter från KI

Kalenderhändelser från KI